Signal Transduction Pathways and Transcriptional Mechanisms of ABCB1/Pgp-mediated Multiple Drug Resistance in Human Cancer Cells

被引:128
作者
Sui, H. [1 ]
Fan, Z-Z [1 ]
Li, Q. [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Dept Oncol, Putuo Hosp, Intervent Canc Inst Chinese Integrat Med, Shanghai 200062, Peoples R China
关键词
MULTIPLE DRUG RESISTANCE (MDR); SIGNAL TRANSDUCTION PATHWAY; P-GLYCOPROTEIN; ABCB1; CANCER; NF-KAPPA-B; MEDIATED MULTIDRUG-RESISTANCE; ACTIVATED PROTEIN-KINASE; MDR1; GENE-EXPRESSION; P-GLYCOPROTEIN; OVARIAN-CANCER; PROSTATE-CANCER; BREAST-CANCER; PKC-ALPHA; C-JUN;
D O I
10.1177/147323001204000204
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Multiple drug resistance (MDR), defined as the ability of tumour cells to survive exposure to many chemotherapeutic agents, is a major cause of treatment failure in human cancers. The membrane transporter P-glycoprotein (Pgp, encoded by the ABCB1 [adenosine triphosphate-binding cassette, subfamily B, member 1] gene) is the main mechanism for decreased intracellular drug accumulation in human MDR cancer. ABCB1/Pgp-mediated MDR involves several signal transduction pathways and transcription factors. Activation of these signal transduction pathways influences the prognosis of MDR human cancer. Signalling pathways involved in ABCB1/Pgp-mediated MDR include the mitogen-activated protein kinase (MAPK), c-Jun NH2-terminal kinase (JNK), p38, cyclic adenosine monophosphate-dependent protein kinase, phosphatidylinositol 3-kinase and protein kinase C signalling pathways. This review summarizes the biological characteristics, target points and signalling cascade mediators of these pathways. Drugs targeted against these pathways may provide new therapies for treatment of ABCB1/Pgp-mediated MDR.
引用
收藏
页码:426 / 435
页数:10
相关论文
共 76 条
[1]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]   Multiple Drug Resistance Mechanisms in Cancer [J].
Baguley, Bruce C. .
MOLECULAR BIOTECHNOLOGY, 2010, 46 (03) :308-316
[3]   SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance [J].
Barancík, M ;
Bohácová, V ;
Kvackajová, J ;
Hudecová, S ;
Krizanová, O ;
Breier, A .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (01) :29-36
[4]   PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB [J].
Bark, H. ;
Choi, Cheol-Hee .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) :1131-1136
[5]   Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-α (PKC-α) pseudosubstrate peptides through a P-glycoprotein-independent mechanism [J].
Bergman, PJ ;
Gravitt, KR ;
Ward, NE ;
Beltran, P ;
Gupta, KP ;
O'Brian, CA .
INVESTIGATIONAL NEW DRUGS, 1997, 15 (04) :311-318
[6]  
BLOBE GC, 1993, J BIOL CHEM, V268, P658
[7]  
Brügger D, 2002, ANTICANCER RES, V22, P4229
[8]   INTERNAL DUPLICATION AND HOMOLOGY WITH BACTERIAL TRANSPORT PROTEINS IN THE MDR1 (P-GLYCOPROTEIN) GENE FROM MULTIDRUG-RESISTANT HUMAN-CELLS [J].
CHEN, CJ ;
CHIN, JE ;
UEDA, K ;
CLARK, DP ;
PASTAN, I ;
GOTTESMAN, MM ;
RONINSON, IB .
CELL, 1986, 47 (03) :381-389
[9]  
Childs S, 1994, Important Adv Oncol, P21
[10]   MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome [J].
Cizmarikova, M. ;
Wagnerova, M. ;
Schonova, L. ;
Habalova, V. ;
Kohut, A. ;
Linkova, A. ;
Sarissky, M. ;
Mojzis, J. ;
Mirossay, L. ;
Mirossay, A. .
PHARMACOGENOMICS JOURNAL, 2010, 10 (01) :62-69